famotidine has been researched along with Methemoglobinemia in 1 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Methemoglobinemia: The presence of methemoglobin in the blood, resulting in cyanosis. A small amount of methemoglobin is present in the blood normally, but injury or toxic agents convert a larger proportion of hemoglobin into methemoglobin, which does not function reversibly as an oxygen carrier. Methemoglobinemia may be due to a defect in the enzyme NADH methemoglobin reductase (an autosomal recessive trait) or to an abnormality in hemoglobin M (an autosomal dominant trait). (Dorland, 27th ed)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Malfará, WR | 1 |
Pereira, CP | 1 |
Santos, AC | 1 |
Queiroz, RH | 1 |
1 other study available for famotidine and Methemoglobinemia
Article | Year |
---|---|
Effects of H(2)-receptor antagonists on dapsone-induced methaemoglobinaemia in rats.
Topics: Animals; Biotransformation; Dapsone; Dose-Response Relationship, Drug; Drug Interactions; Famotidine | 2002 |